EANS-Adhoc: Marinomed Biotech AG announces strong investor demand and expected offer price

--------------------------------------------------------------------------------
Disclosed inside information pursuant to article 17 Market Abuse Regulation
(MAR) transmitted by euro adhoc with the aim of a Europe-wide distribution.
The issuer is responsible for the content of this announcement.
--------------------------------------------------------------------------------

Stock Offerings (IPO)
29.01.2019

Vienna - 29 January 2019. Marinomed Biotech AG has already received subscription
orders for more than 299,000 new bearer shares (base deal incl. 15% over-
allotment /Greenshoe) as part of the current IPO and listing on the Vienna Stock
Exchange (the "Offering"). The transaction meets the requirements of a qualified
public offer in accordance with the terms and conditions of the convertible
bonds issued in 2017 that are traded on the Third Market of the Vienna Stock
Exchange. The Offer Price is expected to be EUR 75 per share. No adjustment of
the Conversion Price I (as defined in the terms and conditions of the
convertible bonds) is therefore expected to be necessary.

The Offer Period will end today at 12.00 CET for retail investors and at 17.00
CET for institutional investors. The expected settlement date and first trading
day is 1 February 2019. From this date the Marinomed shares are intended to be
traded under the symbol "MARI" on the official market (prime market segment) of
the Vienna Stock Exchange.

About Marinomed Biotech AG
Marinomed Biotech AG is a Vienna based biopharmaceutical company focusing on the
development of innovative products derived from patent protected technology
platforms to treat respiratory and ophthalmic conditions. The Carragelose®
platform comprises innovative patent protected products targeting viral
infections of the respiratory tract. Carragelose® is used in nasal sprays,
throat sprays and lozenges, which are sold in more than 30 countries around the
world in collaboration with international partners.The Marinosolv® technology
platform increases the efficacy of hardly soluble compounds for the treatment of
sensitive tissues such as the eyes and nose. Further information is available at
www.marinomed.com.

Disclaimer

This announcement does not constitute an offer to purchase securities or
solicitation of an offer to purchase securities in the United States of America,
Germany, Austria or other jurisdictions. The shares (the "Shares") of Marinomed
Biotech AG (the "Company") may only be sold or offered for sale after prior
registration in the United States of America upon or without prior registration
by virtue of an exemption from the registration requirement under the provisions
of the US Securities Act of 1933, as amended. The Company does not intend to
fully or partially register any offer of Shares in the United States or to make
any public offering of Shares in the United States.

A public offering of securities of the Company in Austria is made solely by, and
on the basis of, a prospectus (including the supplements thereto) for securities
prepared and published in accordance with the provisions of the Capital Markets
Act (Kapitalmarktgesetz), which was approved and published on 16 November 2018.
An investment decision regarding publicly offered securities of the Company
should only be made on the basis of such a prospectus. The prospectus as well as
the supplements thereto are available free of charge at Marinomed Biotech AG,
Veterinärplatz 1, A-1210 Vienna, or on the website of Marinomed Biotech AG
(https://www.marinomed.com/offering).

Further inquiry note:
Eva Prieschl-Grassauer, PhD
Chief Scientific Officer, Marinomed
Veterinärplatz 1, 1210 Vienna, Austria
Tel.: +43 (0)1 250 77 4460
E-mail: eva.prieschl@marinomed.com
http://www.marinomed.com

Roland Mayrl
Managing Partner, Metrum Communications
Prinz-Eugen-Straße 80/16, 1040 Vienna, Austria
Tel.: +43 (0) 1 504 69 87 331
E-mail: r.mayrl@metrum.at
http://www.metrum.at

end of announcement euro adhoc
--------------------------------------------------------------------------------

issuer: Marinomed Biotech AG
Veterinärplatz 1
A-1210 Wien
phone: 0043250774460
FAX: 0043250774493
mail: office@marinomed.com
WWW: www.marinomed.com
ISIN: AT0000A1WD52
indexes:
stockmarkets: Wien
language: English

Original-Content von: Marinomed Biotech AG, übermittelt durch news aktuell